查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
外阴阴道念珠菌病治疗市场 - 全球行业规模、份额、趋势、机会和预测，2018-2028 年，按药物类别、给药途径、分销渠道、按地区细分、竞争
市场调查报告书
商品编码
1244139

外阴阴道念珠菌病治疗市场 - 全球行业规模、份额、趋势、机会和预测，2018-2028 年，按药物类别、给药途径、分销渠道、按地区细分、竞争

Vulvovaginal Candidiasis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Drug Class, By Route of Administration, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

在预测期内，全球外阴阴道念珠菌病治疗市场预计将出现显着增长。

这是由于新型抗真菌药物的不断开发和全球医疗保健支出的增加。 此外，随着老年人口的不断增加，对低成本、同类最佳治疗的需求不断增长，世界各地区对外阴阴道念珠菌病药物的需求正在显着增加。 此外，全球癌症、心血管疾病、神经系统疾病和糖尿病等慢性病患病率的上升也将增加外阴念珠菌病治疗的需求，并推动市场增长至 2028 年。预计 此外，在预测期内，人们对保持良好卫生意识的提高以及获得新疗法的廉价途径的优势预计将进一步支持外阴阴道念珠菌病治疗市场。 此外，由于酵母菌感染导致氟康唑等广谱抗生素的使用增加，预计将增加对外阴阴道念珠菌病药物的需求并支持市场增长。 它是美国第二常见的阴道感染类型，仅次于细菌性阴道感染。 据估计，每年因阴道念珠菌病就诊的门诊人数约为 140 万。

阴道念珠菌病流行率上升推动市场增长

由于急性外阴念珠菌病感染在人群中的流行率不断上升，预计未来外阴念珠菌病市场将会增长。 此外，越来越多的研究检查外阴念珠菌病和 RVVC 的流行也有望促进该部分的增长。 例如，根据《柳叶刀》杂誌发表的文章“传染病分部：2018”，全球约有 1.38 亿女性患有復发性外阴念珠菌病（急性外阴念珠菌病 12 个月内至少发作 3 次），每 10 万人中有 3871 名女性患有每年来自外阴念珠菌病。 此外，慢性病在全球范围内的扩散、对更好治疗的需求不断增长以及医院获得性感染的增加也推动了对外阴阴道念珠菌病药物的需求。 此外，新兴国家医疗保健支出的增加、肥胖和糖尿病患病率的上升、政府资金的增加以及政府和私人组织为传播对该疾病及其预防措施的认识而采取的更多举措都促进了外阴阴道念珠菌病的发展。它是扩大疾病治疗市场的一个因素。

激活研发活动是市场发展的动力

在预测期内，外阴念珠菌病药物和治疗药物研发的增加预计将促进全球外阴念珠菌病市场的增长。 2020 年 4 月，Scynexis Inc.宣布了一项令人鼓舞的第 3 期试验结果，该试验旨在确认抗真菌药物 Ibrexafungerp 治疗 VVC 的疗效。 此外，主要的关键参与者已经向监管机构提交了治疗阴道感染的药物，这将使新药的生产成为可能。 预计这些因素将在预测期内推动市场增长。 例如，2021 年 2 月，专注于开发药物和药物治疗真菌感染的生物技术公司 SCYNEXIS, Inc. 与全球领先的合同商业化组织之一 Amplify Health 合作开发的 Brexafemme（Ibrexafungerp）在美国上市美国。

近期发展

2021 年 2 月，生物技术公司 Scynexis 和製药公司 Amplify Health 扩大了对 Ibrexafungerp 品牌名称 BrexafemmeTM 用于阴道感染的美国商业化的支持。宣布了一项协议。

2019年10月，美国製药公司Mycovia Pharmaceuticals宣布将与匈牙利製药公司Gedeon Richter合作生产外阴阴道念珠菌病治疗药物VT-1161。

竞争格局

公司概况：对全球外阴阴道念珠菌病治疗市场主要参与者的深入分析。

可自定义：

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

  • 对其他市场参与者（最多 5 家）进行深入分析和概况分析。

内容

第 1 章概述

  • 市场定义
  • 市场范围
    • 目标市场
    • 研究目标年份
    • 主要市场细分

第二章研究方法论

  • 调查目的
  • 基线调查方法
  • 主要行业合作伙伴
  • 主要协会和次要信息
  • 调查方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章执行摘要

  • 市场概览
  • 主要市场细分概述
  • 主要市场参与者概览
  • 主要地区/国家概览
  • 市场驱动因素、挑战和趋势概述

第 4 章 VOC（客户之声）

第5章临床试验分析

  • 正在进行的临床试验
  • 已完成临床试验
  • 已完成临床试验
  • 管道细分（按开发阶段）
  • 管道细分（按状态
  • 管道细分（按研究类型）
  • 按地区划分的渠道细分
  • 临床试验热图

第 6 章外阴阴道念珠菌病治疗的全球市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按药物类别（克霉唑、制霉菌素、氟康唑、酮康唑、特比□芬、特康唑等）
    • 按给药途径（口服、静脉内、局部）
    • 按分销渠道（医院药店、零售药店、在线药店）
    • 按地区
    • 按公司分类（2022 年）
  • 市场地图
    • 按治疗类别
    • 按给药途径
    • 按分销渠道
    • 按地区

第 7 章北美外阴阴道念珠菌病治疗市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按治疗类别
    • 按给药途径
    • 按分销渠道
    • 按国家
  • 北美：国家/地区分析
    • 美国
    • 加拿大
    • 墨西哥

第八章欧洲外阴阴道念珠菌病药物市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按治疗类别
    • 按给药途径
    • 按分销渠道
    • 按国家
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第九章亚太地区外阴阴道念珠菌病药物市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按治疗类别
    • 按给药途径
    • 按分销渠道
    • 按国家
  • 亚太地区：国家/地区分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第十章：南美外阴阴道念珠菌病药物市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按治疗类别
    • 按给药途径
    • 按分销渠道
    • 按国家
  • 南美洲：：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章中东和非洲外阴阴道念珠菌病药物市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按治疗类别
    • 按给药途径
    • 按分销渠道
    • 按国家
  • MEA：国家分析
    • 南非外阴阴道念珠菌病治疗
    • 沙特阿拉伯外阴阴道念珠菌病治疗
    • 阿联酋外阴阴道念珠菌病治疗

第 12 章市场动态

  • 司机
  • 任务

第13章市场趋势与发展

  • 近期趋势
  • 併购
  • 产品发布

第14章竞争格局

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（As Reported）
  • Key Personnel
  • SWOT Analysis
    • Astellas Pharma Inc.
    • Mycovia Pharmaceuticals, Inc.
    • Basilea Pharmaceutica Ltd.
    • Scynexis, Inc.
    • Grupo Ferrer Internacional, S.A.
    • Pfizer, Inc.
    • Pacgen Life Science Corporation
    • NovaDigm Therapeutics, Inc.
    • Cidara Therapeutics, Inc.
    • Amplyx Pharmaceuticals Inc.

第15章 战略建议

简介目录
Product Code: 14395

The Global Vulvovaginal Candidiasis Treatment Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing development of new antifungal drugs and growing healthcare expenditure across the globe. Additionally, the growing demand for the best treatment with a low cost, along with the growing geriatric population has significantly increased the demand for vulvovaginal candidiasis treatment across different parts of the globe. Additionally, the increasing prevalence of chronic diseases like cancer, cardiovascular diseases, neurological diseases, and diabetes across the globe is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby fuelling market growth through 2028. Besides, growing awareness of maintaining hygiene and the benefits of using new treatments with lower costs is further expected to support the vulvovaginal candidiasis treatment market during the forecast period. Furthermore, increasing usage of a broad-spectrum antibiotic such as Fluconazole because of yeast infection is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby supporting the market growth. It is the second most common type of vaginal infection after bacterial vaginal infections, in the United States. An estimated 1.4 million outpatient visits for vaginal candidiasis occur annually.

Growing Prevalence of Vaginal Candidiasis Is Driving the Market Growth

The growing prevalence of acute vulvovaginal candidiasis infection among the population is expected to grow in the vulvovaginal candidiasis market in the future. An increasing number of research to find the prevalence of the VVC or RVVC is also expected to boost segment growth. For instance, according to the article published in the Lancet Journal, Infectious diseases segment: 2018, globally, approximately 138 million women suffer from recurrent vulvovaginal candidiasis (relapse of acute vulvovaginal candidiasis, at least three times, within twelve months) and 3,871 per 100,000 women suffer from vulvovaginal candidiasis every year. Rapidly increasing chronic diseases across the globe, along with escalating demand for better treatment options and the increasing number of hospital-acquired infections, are also propelling the demand for vulvovaginal candidiasis treatment. Furthermore, growing healthcare expenditure in emerging countries, rising incidence of obesity and diabetes, growing government funding, and rising initiatives by government and private organizations to spread awareness about the disease and its preventive measures are the factors that will expand the vaginal candidiasis treatment market.

Rising Research & Development Activities Will Drive the Market's Growth

Increasing research and development on drugs and treatments for vulvovaginal candidiasis is predicted to boost the growth of the global vulvovaginal candidiasis market during the forecast period. In April 2020, Scynexis Inc. revealed the promising results of Phase III trials which were conducted to check the effectiveness of an anti-fungal drug, Ibrexafungerp for treating VVCs. Also, major key players are applying a new drug for treating vaginal infection to the regulatory bodies which will allow them to manufacture new drugs. These factors are expected to drive market growth in the forecast period. For instance, in February 2021, SCYNEXIS, Inc. a biotechnology company focused on developing therapies and drugs for fungal infections partnered with Amplify Health, one of the global leaders in contract commercialization organization, to launch Brexafemme (Ibrexafungerp) in the United States.

Market Segmentation

The global vulvovaginal candidiasis treatment market can be segmented by drug class, route of administration, distribution channel, and region. Based on drug class, the market can be segmented into Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, and Others. Based on the route of administration, the market can be differentiated into Oral, Intravenous, and Topical. Based on distribution channels, the market can be grouped into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global vulvovaginal candidiasis treatment market on account of the growing usage of broad-spectrum antibiotics for yeast infection in the country.

Recent Development

In February 2021, the biotech company, Scynexis announced its agreement with the pharmaceutical company, Amplify Health to extend its support for the U.S. commercialization of BrexafemmeTM which is a brand name of Ibrexafungerp for vaginal infections.

In October 2019, the American pharmaceutical company, Mycovia Pharmaceuticals announced its collaboration with the Hungarian pharmaceutical company, Gedeon Richter to manufacture VT-1161 for the treatment of vulvovaginal candidiasis.

Market Players

Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional, S.A., Pfizer, Inc., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc. are some of the leading players operating in the Global Vulvovaginal Candidiasis Treatment Market.

Report Scope:

In this report, global vulvovaginal candidiasis treatment market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vulvovaginal Candidiasis Treatment Market, By Drug Class:

  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Others

Vulvovaginal Candidiasis Treatment Market, By Route of Administration:

  • Oral
  • Intravenous
  • Topical

Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Vulvovaginal Candidiasis Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Vulvovaginal Candidiasis Treatment Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Vulvovaginal Candidiasis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others)
    • 6.2.2. By Route of Administration (Oral, Intravenous, Topical)
    • 6.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Market Map
    • 6.3.1. By Drug Class
    • 6.3.2. By Route of Administration
    • 6.3.3. By Distribution Channel
    • 6.3.4. By Region

7. North America Vulvovaginal Candidiasis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Vulvovaginal Candidiasis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Canada Vulvovaginal Candidiasis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Mexico Vulvovaginal Candidiasis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel

8. Europe Vulvovaginal Candidiasis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Vulvovaginal Candidiasis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Germany Vulvovaginal Candidiasis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. United Kingdom Vulvovaginal Candidiasis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Italy Vulvovaginal Candidiasis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Spain Vulvovaginal Candidiasis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Vulvovaginal Candidiasis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Vulvovaginal Candidiasis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. India Vulvovaginal Candidiasis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Japan Vulvovaginal Candidiasis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. South Korea Vulvovaginal Candidiasis Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Route of Administration
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Australia Vulvovaginal Candidiasis Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Route of Administration
        • 9.3.5.2.3. By Distribution Channel

10. South America Vulvovaginal Candidiasis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Vulvovaginal Candidiasis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Argentina Vulvovaginal Candidiasis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Colombia Vulvovaginal Candidiasis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Route of Administration
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Vulvovaginal Candidiasis Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Route of Administration
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Saudi Arabia Vulvovaginal Candidiasis Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Route of Administration
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. UAE Vulvovaginal Candidiasis Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Route of Administration
        • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Astellas Pharma Inc.
    • 14.6.2. Mycovia Pharmaceuticals, Inc.
    • 14.6.3. Basilea Pharmaceutica Ltd.
    • 14.6.4. Scynexis, Inc.
    • 14.6.5. Grupo Ferrer Internacional, S.A.
    • 14.6.6. Pfizer, Inc.
    • 14.6.7. Pacgen Life Science Corporation
    • 14.6.8. NovaDigm Therapeutics, Inc.
    • 14.6.9. Cidara Therapeutics, Inc.
    • 14.6.10. Amplyx Pharmaceuticals Inc.

15. Strategic Recommendations